A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia

Christine S.M. Lee,1,2 Hai Po Helena Liang,1,2 David E. Connor,3,4 Agnibesh Dey,1 Ibrahim Tohidi-Esfahani,1 Heather Campbell,1 Shane Whittaker,1 David Capraro,2 Emmanuel J. Favaloro,5–7 Dea Donikian,8 Mayuko Kondo,8 Sarah M. Hicks,9 Philip Y.-I. Choi,9 Elizabeth E. Gardiner,9 Lisa Joanne Clarke,2,10 Huyen Tran,11,12 Freda H. Passam,13 Timothy Andrew Brighton,8 and Vivien M. Chen1,2,14

1 ANZAC Research Institute, University of Sydney, Sydney, NSW, Australia; 2 Department of Haematology, Concord Repatriation General Hospital and NSW Health Pathology, Sydney, NSW, Australia; 3 Blood, Stem Cell and Cancer Research Laboratory, St. Vincent’s Centre for Applied Medical Research, St. Vincent’s Hospital, Darlinghurst, NSW, Australia; 4 St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; 5 Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia; 6 Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia; 7 Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital, Westmead, NSW, Australia; 8 Department of Haematology, New South Wales Health Pathology, Prince of Wales Hospital, Sydney, NSW, Australia; 9 ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia; 10 Australian Red Cross Lifeblood, Sydney, NSW, Australia; 11 Clinical Haematology Department, The Alfred Hospital, Melbourne, VIC, Australia; 12 Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia; 13 Central Clinical School, University of Sydney, Sydney, NSW, Australia; and 14 Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe prothrombotic complication of adenoviral vaccines, including the ChAdOx1 nCoV-19 (Vaxzevria) vaccine. The putative mechanism involves formation of pathological anti–platelet factor 4 (PF4) antibodies that activate platelets via the low-affinity immunoglobulin G receptor FcγRIIa to drive thrombosis and thrombocytopenia. Functional assays are important for VITT diagnosis, as not all detectable anti-PF4 antibodies are pathogenic, and immunoassays have varying sensitivity. Combination of ligand binding of G protein–coupled receptors (protease-activated receptor-1) and immunoreceptor tyrosine–based activation motif–linked receptors (FcγRIIa) synergistically induce procoagulant platelet formation, which supports thrombin generation. Here, we describe a flow cytometry–based procoagulant platelet assay using cell death marker GSAO and P-selectin to diagnose VITT by exposing whole blood to patient plasma in the presence of a protease-activated receptor-1 agonist. Consecutive patients triaged for confirmatory functional VITT testing after screening using PF4/heparin ELISA were evaluated. In a development cohort of 47 patients with suspected VITT, plasma from ELISA-positive patients (n = 23), but not healthy donors (n = 32) or individuals exposed to the ChAdOx1 nCov-19 vaccine without VITT (n = 24), significantly increased the procoagulant platelet response. In a validation cohort of 99 VITT patients identified according to clinicopathologic adjudication, procoagulant flow cytometry identified 93% of VITT cases, including ELISA-negative and serotonin release assay–negative patients. The in vitro effect of intravenous immunoglobulin (IVIg) and fondaparinux trended with the clinical response seen in patients. Induction of FcγRIIa-dependent procoagulant response by patient plasma, suppressible by heparin and IVIg, is highly indicative of VITT, resulting in a sensitive and specific assay that has been adopted as part of a national diagnostic algorithm to identify vaccinated patients with platelet-activating antibodies.

Key Points
• VITT plasma induces an FcγRIIa-dependent procoagulant response in donor platelets suppressible by heparin and IVIg.
• Whole-blood procoagulant platelet flow cytometry has diagnostic potential to detect platelet-activating VITT antibodies.

Submitted 24 November 2021; accepted 8 March 2022; prepublished online on Blood Advances First Edition 31 March 2022; final version published online 10 June 2022. DOI 10.1182/bloodadvances.2021006698.

Prior version of this research appeared in abstract form in: https://ashpublications.org/blood/article/138/Supplement%201/3211/479440/Flow-Cytometric-Detection-of-Procoagulant.
Introduction

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe prothrombotic syndrome described in association with adenoviral coronavirus 2 (SARS-CoV-2) vaccination. In Australia, the ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca) vaccine is a key component of the national vaccination program. VITT can be severe and occasionally fatal. Mortality is significantly reduced with early recognition and institution of therapy, including infusion of intravenous immunoglobulin (IVIg) and commencement of nonheparin anticoagulants. The putative mechanism is analogous to heparin-induced thrombocytopenia (HIT), in which pathologic autoantibodies against procoagulant receptors (ITAM)-linked receptors, including FcγRIIa, synergistically induce for-ming of coagulation factors and thrombin generation. Not all immunologically detected anti-PF4 antibodies are pathologic, with 6.8% of anti-PF4 antibodies detectable by screening of well individuals after COVID-19 vaccination. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis suggests that diagnostic VITT samples be tested in one or more HIT functional assays.

Procoagulant platelets (PPs) are a subpopulation of platelets that promote coagulation by providing procoagulant surfaces, enabling assembly of coagulation factors and thrombin generation. Detection of PPs by using a combination of P-selectin (platelet activation marker) and annexin V (phosphatidylserine marker) in the presence of PF4 has been proposed as a diagnostic assay for VITT. PPs are not typically generated in response to low-level agonist stimulation; however, the combination of ligand binding of G protein–coupled receptors (GPCRs) (eg, protease-activated receptor-1 [PAR1]) and immunoreceptor tyrosine–based activation motif (ITAM)-linked receptors, including FcγRIIa, synergistically induce formation of PPs.

PPs are formed in response to VITT antibodies. Here, we describe a PP flow cytometric assay to diagnose VITT by using combinations of a cell death marker, GSAO [4-(N-(S-glutathionylacetyl)amino)phenylarsonic acid], and P-selectin. Platelets identified by GSAO uptake bind active factor X and support thrombin generation, whereas a subset of platelets expressing phosphatidylserine bind active factor X. Thus, GSAO methodology yields more specific identification of functionally relevant PPs. We hypothesized that priming platelets from pedigree donors with a PAR1 agonist at levels sufficient to release PF4, but insufficient to generate significant procoagulant responses, would provide a platform in which measured procoagulant responses would reflect ITAM receptor ligand signaling by FcγRIIa-dependent procoagulant antibodies in patient plasma, without requiring additional PF4.

Methods

Study approval

Human studies were approved by Sydney Local Health District Human Research Ethics Committees (HREC/18/CGRH/294, X21-0160, 2021/ETH00945). Healthy donors gave written informed consent.

Study cohort

Citrated plasma from 47 Australian patients referred for confirmatory VITT testing after ChAdOx1 nCoV-19 vaccination between 1 April 2021 and 11 August 2021 formed the development cohort. Data collected included time to onset of symptoms, platelet count, D-dimer level, site of thrombosis, and treatment initiation. All patients underwent anti-PF4 testing with PF4/heparin ELISA (Aserachrom HPIA IgG Assay, Stago Diagnostics) and VITT functional testing via standard (no exogenous PF4) serotonin release assay (SRA) and/or multiple platelet multiple electrode aggregometry (MEA). Patients with confirmed thrombosis were grouped as follows: (1) confirmed VITT if fulfilling all 5 criteria of (i) vaccine within 4 to 42 days of symptom onset, (ii) thrombocytopenia, (iii) D-dimer level >5 times the upper limit of normal, (iv) anti-PF4/polyanion ELISA positive and (v) SRA positive; (2) VITT negative if (i) ELISA negative, (ii) SRA negative, and (iii) clinically adjudicated not to be VITT; and (3) “ELISA false positive” if (i) ELISA positive, (ii) SRA negative or MEA negative, and (iii) normal platelet count. Comparison was made with plasma from 32 healthy individuals. The flow cytometry assay was assessed in a validation cohort of 99 VITT cases clinically adjudicated by members of the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) advisory group based on clinical-pathologic criteria.

Healthy volunteers

Healthy donors recruited at Concord Hospital and ANZAC Research Institute (Sydney, Australia) were screened as suitable VITT donors in a 2-step process. First, FcγRIIa responders were identified by using light transmission aggregometry (LTA) in response to 1.5 μg/mL of anti-CD9, clone ALB6 (Santa Cruz Biotechnology), as described previously. Second, high responders exhibiting >80% aggregation with a time to initiation <180 seconds were subjected to a second screen and selected as suitable VITT donors if returning concordant results using a plasma panel of patients with known positive, negative, and low positive patterns (supplemental Figure 4). Eleven of 58 individuals were identified by using the LTA screen, and 9 of those 11 were suitable for VITT testing. Group O donors were preferred but not a limitation. Blood was collected from the antecubital fossa into 3.2% citrate tubes using a 21-gauge butterfly needle. The initial 3 mL of blood was discarded.

Procoagulant platelet assay

The GSAO-based whole-blood PP flow cytometry assay was modified to incorporate exogenous plasma. Serum samples were found to be unsuitable for this assay. Citrated whole blood (13 μL) was incubated with and without 5 μM SFLLRN (Ausp-pep), unfractionated heparin (0.5-100 U/mL, Pfizer), and ChA-DOx1 nCoV-19 (1:2000 [vol/vol], AstraZeneca). In some experiments, blood was pretreated with 10 μg/mL IVIg (Privigen, CSL Behring) for 15 minutes before testing. Where indicated, fondaparinux (1.2-100 μg/mL, Arixtra [GlaxoSmithKline]), SARS-CoV-2 spike protein (20 μg/mL HexaPro), or 25 μg/mL native human PF4 purified from expired platelet concentrate was added. A total of 5 μL citrated plasma or buffer was added simultaneously to the reaction mix for 10 minutes, with 2.5 mM Gly-Pro-Arg-Pro peptide (Sigma Aldrich) and 2.5 mM calcium chloride in Hanks balanced salt solution (pH 7.35) in a 50 μL reaction. The reaction was stopped by further dilution with Hanks balanced salt solution, followed by staining with antibodies to CD45 (HI30) (Stemcell Technologies), CD41a (HIP8)
(BD Biosciences), CD62P (Psel.KO2.3) (eBioscience), or isotype control (eBioscience), and GSAO or control compound GSCA [4-((S)-glutathionylethyll)amino]benzoic acid. Samples were fixed with PAMFix (Platelet Solutions Ltd), centrifuged, and resuspended, before analysis on a BD LSRRFortessa X-20 or BD FACSCanto II cytometer with acquisition of 3000 to 7000 platelet events (all steps performed at room temperature). A positive (confirmed VITT patients) and negative (healthy individuals) control plasma was incorporated with each run. Reagents are available on request.

SRA and multiplate MEA

SRA was performed as described with minor modifications, including preincubation with IV.3 (10 μg/mL), and in some cases addition of PF4 (18 μg/mL) purified from expired human platelets. MEA was modified for addition of patient serum (supplemental Methods).

Statistical analyses

Statistical analyses were performed by using GraphPad Prism 9.2 (GraphPad Software), with significance set at $P < .05$. Experimental data are presented as mean ± standard deviation.

Results

Characteristics of patients suspected of having VITT: development cohort

Forty-seven patients (19 female subjects, 28 male subjects) with a median age of 70 years (interquartile range: 58-81 years) referred for confirmatory VITT testing with thrombosis after ChAdOx1 nCoV-19 vaccination were analyzed for the development cohort. Demographic data are summarized in Table 1. Patients with confirmed VITT were significantly younger (median, 65 years vs 74 years; $P = .017$) with lower platelet count (median, $45 \times 10^9/L$ vs $130 \times 10^9/L; P < .0001$) and higher D-dimer levels (median, 10-fold vs 14.4-fold increase above the upper limit of normal; $P = .006$) compared with VITT-negative patients. No significant differences in sex, timing of presentation relative to vaccination, or incidence of thrombosis was observed between VITT-confirmed vs VITT-negative patients. All 23 confirmed VITT patients had thrombosis, including cerebral venous sinus thrombosis ($n = 4$), splanchic vein thrombosis ($n = 4$), pulmonary embolism ($n = 12$), and deep vein thrombosis ($n = 10$). Most VITT-positive patients received IVIg. Forty-six of 47 samples were collected before treatment.

VITT plasma sensitizes healthy platelets to become procoagulant

PPs in whole-blood reactions were detected by flow cytometry and defined as CD41a-positive (platelet-specific marker) events that are GSAO- and P-selectin-positive. In proof-of-principle experiments, donor blood treated with the PAR1 agonist SFLLRN caused release of platelet α-granules represented by P-selectin expression, with minimal PPs formed (Figure 1A-B). Exposing healthy blood to both SFLLRN and plasma containing VITT anti-PF4 antibodies, but not plasma from a patient with sepsis, resulted in a synergistic effect, whereby a dramatic increase in PP proportion was observed by flow cytometry and evidence of ballooning with GSAO uptake by microscopy. In the development cohort (47 patients), minimal PPs (3.9% ± 1.0%) were generated by donor blood treated with SFLLRN (Figure 1C). Addition of plasma from healthy individuals (3.6% ± 1.4%), or ChAdOx1 nCoV-19 vaccinated patients with thrombocytopenia and thrombosis but without detectable anti-PF4 antibodies (VITT-negative, 4.5% ± 2.1%), or ELISA false-positive patients (3.9% ± 0.8%), did not increase the procoagulant response in donor platelets. However, addition of plasma from confirmed VITT patients significantly increased PP response (25.7% ± 17.7%) compared with no plasma ($P < .0001$), healthy ($P < .0001$), VITT-negative ($P < .0001$), or ELISA false-positive ($P = .0381$) samples. The PP proportions induced by VITT plasma varied between patients (range, 5.7%-63.0%).

VITT-induced PP response is suppressed by heparin

To explore whether charged molecules affected VITT-induced PP response, low-dose (0.5 U/mL) and high-dose (100 U/mL) heparin was added to the reaction. Low-dose heparin significantly reduced PP response (25.7% ± 17.7%) compared with no plasma ($P < .0001$), healthy ($P < .0001$), VITT-negative ($P < .0001$), or ELISA false-positive ($P = .0381$) samples. The PP proportions induced by VITT plasma varied between patients (range, 5.7%-63.0%).

Table 1. Laboratory and clinical characteristics of patients suspected of VITT in the development cohort

| Variable                  | All (N = 47) | VITT positive (n = 23) | VITT negative (n = 20) | ELISA false positive (n = 4) | $P^*$  |
|---------------------------|-------------|------------------------|------------------------|-----------------------------|-------|
| Sex                       |             |                        |                        |                             |       |
| Female                    | 19          | 11                     | 6                      | 2                           | .350  |
| Male                      | 28          | 12                     | 14                     | 2                           |       |
| Age, y                    | 70 (58-81)  | 65 (52-75)             | 74 (63-83)             | 69 (50-84)                  | .017  |
| Days postvaccine          | 10 (7-17)   | 9 (8-14)               | 12 (5-20)              | 8 (7-15)                    | .912  |
| Platelet count (×10⁹/L)   | 85 (39-135) | 45 (30-65)             | 130 (114-143)          | 232 (209-255)               | <.0001|
| D-dimer (fold-change over ULN) | 33.8 (9.4-40) | 40 (30-70)              | 14.4 (5.1-28.3)        | <5× ULN in 3 patients       | .006  |
| Thrombocytopenia          | 45          | 23                     | 19                     | 3                           | .465  |

Continuous variables are expressed as median (interquartile range). ULN, upper limit of normal.

$^*$Fisher’s exact test (categorical variables) or Mann-Whitney U test (continuous variables) between VITT-positive and VITT-negative groups. $P < .05$ are in bold.
response was variable, with 0.1- to 1.0-fold (0.4 ± 0.2-fold) change from plasma alone. Interestingly, 3 of 23 patients exhibited an enhanced PP response, with low-dose heparin similar to the procoagulant response induced by HIT plasma (Figure 2B). In all cases, PP response was completely abolished with high-dose heparin (VITT, 3.5% ± 1.4% vs 25.7% ± 17.7% [P < .0001]; HIT, 3.5% ± 1.0% vs 42.8% ± 12.1% [P < .0001]).
VITT-induced PP response requires FcγRIIa and can be inhibited by IVIg

Donor platelets pretreated with FcγRIIa function-blocking antibody IV.3 or IVIg before exposure to patient plasma showed that PP response is mediated through FcγRIIa and induced by antibodies. Regardless of extent of the PP response, the PP proportion was significantly reduced to baseline levels with IV.3 (4.5 ± 1.7 vs 25.8 ± 17.8; \( P < .0001 \)) (Figure 2C). Although IVIg significantly decreased PP proportions induced by VITT plasma (6.4 ± 5.2 vs 25.8 ± 17.8; \( P < .0001 \)) (Figure 2D), the extent of inhibition varied whereby partial inhibition was observed in some patients.

Figure 2. PP response induced by VITT plasma is suppressed by heparin, is antibody mediated, and corresponded with clinical response to therapy.

Healthy donor whole blood was treated with platelet agonist 5 μM SFLLRN and plasma from patients with VITT (n = 23) (A) or HIT (n = 8) (B) in the presence of low-dose (0.5 U/mL) or high-dose (100 U/mL) unfractionated heparin and assessed for PP formation by using flow cytometry. Blue lines represent patients with VITT who generated a heparin-enhancing PP response at low-dose heparin. Friedman test with Dunn’s correction for multiple comparisons was performed. Donor blood was pretreated with the FcγRIIa-blocking antibody IV.3 (10 μg/mL) (C) or IVIg (10 mg/mL) (D) for 15 minutes before exposure to VITT plasma and 5 μM SFLLRN. Wilcoxon matched-pairs signed rank test was performed. (E) PP response induced by VITT plasma (n = 4) collected pre-IVIg treatment was compared with the procoagulant response within 5 days’ post-IVIg therapy. The reduction in the PP response corresponded to the suppressive effect of exogenous IVIg (10 mg/mL) on the pre-IVIg sample. Results are presented as fold-change in PP proportion relative to no plasma control. Each line represents a unique patient. (F) Plasma samples from 6 patients with VITT collected before initiation of fondaparinux treatment was tested in the presence of fondaparinux (1.2 μg/mL) in vitro. PP response is normalized to no fondaparinux control. Four patients were subsequently found to be clinically responsive to fondaparinux, and 2 patients were fondaparinux resistant. Healthy donor whole blood was treated with platelet agonist 5 μM SFLLRN and VITT plasma in the presence of the ChAdOx1 nCoV-19 vaccine (AZD1222, 1:2000 [vol/vol], n = 23) (G) or recombinant SARS-CoV-2 spike protein (HexaPro 20 μg/mL, n = 10) (H) before flow cytometric assessment for PP formation. Wilcoxon matched-pairs signed rank test was performed. *\( P < .05 \), **\( P < .01 \), ***\( P < .001 \), ****\( P < .0001 \). ns, not significant.
In vitro PP response to clinical therapies

Given that IVIg is recommended for treating VITT,4,5 we evaluated whether in vitro responses to IVIg could inform in vivo clinical response to IVIg therapy using confirmed cases collected both before and within 5 days of IVIg infusion (Figure 2E). Post-IVIg samples exhibited a procoagulant response similar to that of the pre-IVIg sample with exogenous IVIg. Nonheparin anticoagulants such as the synthetic factor Xa inhibitor (modeled on heparin pentasaccharide sequence) fondaparinux are used in VITT therapy.4,5 Treatment of SRA-confirmed HIT with fondaparinux resulted in mixed outcomes,23 and similar “resistance” may also occur in VITT. We compared the effect of exogenous fondaparinux on PP response induced by

Figure 3. Diagnostic potential of PP flow cytometry assay in identifying VITT plasma. (A) Receiver-operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic potential of fold-increase compared with no plasma baseline in PP formation in healthy donors induced by plasma from patients with confirmed VITT (n = 23) who tested positive on both ELISA and SRA, and VITT-negative patients (n = 24) who tested negative on both ELISA and SRA, and ELISA false-positive patients who are non-thrombocytopenic and SRA-negative. (B) ROC analysis of the fold-change in PP proportion in the presence of the FcγRIIa-blocking antibody IV.3 (10 μg/mL) relative to SFLLRN alone. Supplemental Tables 1 and 2 provide lists of sensitivity and specificity at various cutoff values. Representative patterns of PP response demonstrating classical VITT (C), heparin-enhancing VITT (D), and negative profile (E). PP response of individual patients in the development cohort are shown in panels F, G, and H. Dotted horizontal line represents no plasma baseline. AUC, area under the curve.
| Sex | Age (y) | Platelet count (× 10^9/L) | D-dimer (fold-change) | Thrombosis | ELISA | ELISA OD | Flow cytometry | SRA | Multiplate | Serologically confirmed VITT |
|-----|--------|--------------------------|----------------------|------------|-------|----------|---------------|-----|------------|---------------------------|
|     |        |                          |                      |            |       |          | Standard      | PF4 enhanced | Standard | PF4 enhanced |                          |
|     |        |                          |                      |            |       |          | Classical VITT | NT            |          | Classical VITT |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Positive      | NT            |          | Positive     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |
|     |        |                          |                      |            |       |          | Negative      | NT            |          | Negative     |                          |
|     |        |                          |                      |            |       |          | NT            | NT            |          | NT          |                          |

CVST, cerebral venous sinus thrombosis; DVT, deep vein thrombosis; F, female; ICA, internal carotid artery; LL, lower limb; M, male; MCA, middle cerebral artery; NA, not available; NT, not tested; OD, optical density; PE, pulmonary embolism.
Inhibition of the PP response was reported at control concentrations aimed to disrupt charge-related interactions (100 μg/mL fondaparinux). At the therapeutic fondaparinux concentration (1.2 μg/mL), we observed a decreasing trend in PP response induced by plasma from 4 patients who clinically responded to fondaparinux therapy (Figure 2F). In contrast, no change in PP response was seen with fondaparinux when tested with plasma from patients who did not respond clinically. No relationship between response and ELISA optical density was detected (supplemental Figure 1).

**Addition of ChAdOx1 nCoV-19 and SARS-CoV-2 spike protein resulted in an inconsistent effect on procoagulant response**

Exogenous ChAdOx1 nCoV-19 did not induce a procoagulant response in the absence of VITT plasma (supplemental Figure 2). Addition of ChAdOx1 nCoV-19 enhanced PP response in some, but not all, patients with VITT (Figure 2G). The procoagulant response generated by 3 patients with heparin-enhancing VITT was reduced in the presence of vaccine. Overall, there was no significant change in PP response induced by 23 VITT plasmas in the presence of vaccine (27.1 ± 19.1 vs 25.8 ± 17.8; P = .6273).

Inclusion of HexaPro, a recombinant form of SARS-CoV-2 spike protein containing 6 amino acid substitutions for stable expression, did not significantly change the PP response generated by 10 VITT patient plasmas (25.5 ± 14.4 vs 23.6 ± 14.8; P = .3223) (Figure 2H). A positive, but nonsignificant, trend (Pearson r = 0.538; P = .1090) (supplemental Figure 3) was observed between the effect of ChAdOx1 nCoV-19 and HexaPro on VITT plasma-induced PP response.

**Diagnostic utility of PP assay**

To evaluate the diagnostic potential, a receiver-operating characteristic curve was generated using plasma from patients with confirmed VITT (n = 23) who tested positive on both ELISA and SRA, and VITT-negative patients (n = 24) comprising ELISA-negative and SRA-negative patients, and ELISA false-positive patients who were non-thrombocytopenic and SRA negative. The area under the curve was 0.97 ± 0.02 (P < .0001) with a cutoff of 1.7-fold increase in plasma-induced PP formation demonstrating 100% sensitivity and 91.7% specificity (Figure 3A; supplemental Table 1). Suppression of PP response by IV.3-mediated blockade of FcγRIIa may further discriminate between antibody-mediated (VITT) and non-antibody-mediated (non-VITT) procoagulant response. A <0.80-fold change with IV.3 achieved 100% sensitivity and 91.3% specificity, with an area under the curve of 0.99 ± 0.01 (P < .0001) (Figure 3B; supplemental Table 2) and identified individuals with non-antibody-mediated PP enhancement.

**Pattern of PP response in VITT**

Figure 3C-H presents the patterns of PP response used in reporting. A pattern we termed “classical VITT” shows the increase in PP compared with baseline with reduction in the presence of 0.5 U/mL heparin, abolition in the presence of 100 U/mL heparin, and at least a 0.80-fold decrease with IV.3. The pattern we termed “heparin-enhancing VITT” exhibits the same as classical VITT but with an increased PP response in the presence of 0.5 U/mL heparin. An equivocal (non-antibody-mediated procoagulant) response shows an increase in PP but without reduction with IV.3 regardless of other reactivity.

**Evaluation of utility of standard flow cytometry assay in case ascertainment**

Analysis of 108 cases referred for functional testing within the first 2.5 months of VITT in Australia (Table 2) found 59 cases consistent with VITT. No “VITT-negative” patients had a positive flow cytometry assay. Of the 59 patients with VITT, results of 41 cases were concordant between ELISA, standard SRA, and flow cytometry. Four patients who tested positive on both standard SRA and flow cytometry were ELISA negative but classified as VITT by the THANZ VITT advisory group who would have been missed using ELISA criteria alone. Fourteen patients were positive by standard flow cytometry who were missed by initial standard SRA testing. Thirteen of 14 were VITT serologically supported by either ELISA, PF4-enhanced SRA, or MEA as functional assays indicating likely true positive findings. One of 14 was clinically adjudicated to be VITT without additional serologic support. This standard flow cytometry assay enabled 7.4% cases in this cohort to be classified as VITT that would otherwise be missed by ELISA and 14.8% cases missed by standard SRA.

**Addition of PF4 in clinically high probability cases that are negative in standard flow cytometry**

Addition of exogenous PF4 has shown improved sensitivity of functional platforms to detect platelet-activating antibodies in VITT. We investigated the effect of purified human PF4 on performance of our flow cytometry assay using plasma from confirmed VITT-positive and VITT-negative cases. Exogenous PF4 did not alter results of VITT-positive (n = 6) or VITT-negative (n = 8) cases reported by standard flow cytometry assay without PF4 (Figure 4A). Plasma samples that were inconclusive or negative in our standard assay, but positive via SRA or PF4-SRA, were tested with exogenous PF4 addition to flow cytometry. Two of 3 patients who were equivocal or inconclusive according to standard flow cytometry became positive, whereas one remained equivocal after PF4 addition (Table 2). Three of 5 patients who were thought to be false negative on standard flow cytometry (SRA positive) were labeled positive with PF4-enhanced flow cytometry.

**Performance of flow cytometry assay in cases referred for VITT testing**

Of 99 cases adjudicated as VITT by the THANZ VITT advisory group from 1 April 2021 to 7 September 2021 (Table 3), 98 underwent flow cytometry testing. Four patients had no serologic support by either ELISA or any functional test platform. Seventy-six of the remaining 94 were positive on flow cytometry without PF4 enhancement. Fifteen of 18 individuals classified as negative, inconclusive, or equivocal returned a positive result with PF4 enhancement (Figure 4B). Three remained equivocal (increased procoagulant response to plasma without IV.3 suppression). Overall, 93% of patients with clinicopathologic adjudication of VITT were detectable by flow cytometry assay with sequential testing of negative and equivocal samples with addition of exogenous PF4. PP formation showed a positive correlation with anti-PF4 antibody (r = 0.406; P < .0001) (Figure 4C) and D-dimer (r = 0.315; P = .002) (Figure 4D) levels, and negative correlation against platelet count (r = −0.386; P < .0001) (Figure 4E).
Figure 4. PF4 enhanced PP flow cytometry. Plasma samples from 6 VITT-positive patients and 8 VITT-negative patients previously tested on the standard flow cytometry assay (A) or 15 individuals classified as negative, inconclusive, or equivocal on the standard assay were retested on the PF4 enhanced assay (B). Green line represents a patient with heparin-enhancing response. Donor whole blood was treated with platelet agonist 5 μM SFLLRN and patient plasma in the presence of 25 μg/mL purified native human PF4, unfractionated heparin (0.5 U/mL or 100 U/mL), and/or FcyRIIa-blocking antibody IV.3 (10 μg/mL). Dotted horizontal line represents 1.7-fold increase above no plasma baseline determined in Figure 3 as the optimal cutoff for VITT. The PP response induced by VITT-positive plasma was correlated with anti-PF4 antibody titer represented by ELISA optical density (OD) values (n = 87) (C), patient platelet count at the time of testing (n = 98) (D), and D-dimer levels represented by fold-change above upper limit of normal (n = 96) (E). All patients recorded a platelet count nadir of <150 x 10^9/L. Spearman correlation analysis was performed.
induced procoagulant activity by IV.3 increased assay speci
onstrating speci
(ELISA-positive, SRA-negative, non-thrombocytopenic patients), dem-
ative exacerbation of procoagulant response. Huynh et al6
epitopes on PF4, thereby triggering immune responses against
between PF4 and ChAdOx1 nCoV-19 using super-resolution
as antibody detection, showing the need for ongoing refinement of VITT
diagnostic assays.29 Our application of functional assays to a large
cohort of patients referred for VITT functional testing in Australia
showed heterogeneity. Overall, the standard procoagulant assay
seems more sensitive than ELISA or SRA, and procoagulant assay
with PF4 was more sensitive again. However, some patients with
platelet-activating antibodies that were detectable by flow cytometry
were not detected by SRA and vice versa. An in-depth comparison
of assays would aid understanding (manuscript in preparation E.J.F.,
C.S.M.L., T.A.B., L.J.C., D.D., M.K., I.T.-E., F.H.P., H.T., and V.M.C.).

Unlike HIT, inclusion of low-dose heparin diminished PP response
induced by VITT plasma except for 3 patients with heparin-
dependent exacerbation of procoagulant response. Huynh et al6
reported that VITT antibodies occupy binding sites similar to heparin
on PF4. Addition of heparin presumably competes with VITT anti-
bodies for PF4 binding, nullifying any platelet-activating effect with
complete abrogation at high-dose heparin. The variability in the
effect of low-dose heparin, whereby partial suppression was
observed in some patients but full suppression was achieved in
others, is consistent with published reports. For instance, 5 of 241
and 3 of 812 VITT sera remained positive in platelet-activation
assays in the presence of 0.2 U/mL heparin.

Through molecular simulations, Baker et al30 found that the nega-
tively charged surface of the ChAdOx1 viral capsid interacts with
positively charged PF4, presumably leading to exposure of neo-
epitopes on PF4, thereby triggering immune responses against
PF4. Consistent with this, Greinacher et al31 reported interactions
between PF4 and ChAdOx1 nCoV-19 using super-resolution
microscopy. Akin to heparin in HIT, these observations suggest that
vaccine components may be cofactors in altering PF4 conformation,
causing exposure of neo-epitopes triggering an immune response.
However, at the concentration tested here, we observed an incon-
sistent effect of ChAdOx1 nCoV-19 on the PP response induced
by VITT plasma.

An ongoing goal is for assays to offer personalized predictors for
patients. This assay can be used to monitor persistence or resolu-
tion of platelet-activating properties of VITT antibodies that may be
discordant to ELISA results, to help guide duration of anticoagulation.\textsuperscript{32} Although in vitro responses cannot be fully correlated with clinical response, we speculate that individuals with “heparin-enhancing” responses would be at risk of thrombus formation/progression in the presence of heparin, similar to patients with HIT, and they should avoid future heparin exposure.\textsuperscript{33} The concordance observed between the in vitro effect of IVlg and fondaparinux on VITT-induced PP response, and the clinical response of these patients to IVlg and fondaparinux therapy, are intriguing. Increased numbers could determine utility in identifying individuals who would benefit from change in anticoagulant or additional immune-suppression therapy.

Our assay offers some advantages over other platelet-activating assays. Use of standard citrated whole blood is practical and provides a more physiological environment for assay reactions, and it requires minimal manipulation of donor platelets. Requiring only 5 \( \mu \)L of plasma per test condition and standard flow cytometers add to practicality. Notably, our standard assay detected the majority of VITT cases without requirement for exogenous PF4. This eliminated potential variability introduced by variable PF4 oligomerization\textsuperscript{34,35} and additional expense. This assay is used in association with other functional assays, within diagnostic pathways of VITT in Australia, demonstrating feasibility of translation to diagnostic settings. To date, >360 patient samples had been tested. The nature of PP being a subset of the whole platelet population rather than an “all-or-nothing” response characteristic of \( \alpha \)-granule and dense granule release detection methods enables detection of heparin enhancement in plasma with strongly activating heparin-independent antibodies. In assays with 100% dense granule release with serum alone, detection of further increases in the presence of low-dose heparin is not possible.

The requirement for suitable donor platelets remains a limitation of all functional platelet assays. Interestingly, although all donors with spontaneous aggregation by LTA in response to anti-CD9 antibody were responsive donors in a PP HIT assay, only a proportion of these donors were suitable for VITT assays (supplemental Figure 4). The contribution of Fc\textgamma RIIa-expressing neutrophils to the procoagulant response observed in our assay remains to be addressed. This assay also does not evaluate the patient’s own platelet PP profile, only the effect of the plasma-containing antibody. The standard assay using SFLLRN to release PF4 did not detect all VITT cases. Sequential testing of initially negative or equivocal samples, with a modified assay in which PF4 was added, increased the VITT patients identified to 93%. In a diagnostic setting, we propose that testing negative samples with exogenous PF4 be performed sequentially to avoid the requirement for exogenous PF4 in \( >80\% \) of referrals.

Fc\textgamma RIIa polymorphisms alter receptor affinity for immunoglobulin G, which may account for variation in donor platelet reactivity\textsuperscript{36} and is associated with thrombosis in HIT\textsuperscript{37,38} and atherosclerosis.\textsuperscript{36} An intrinsic PAR1 gene polymorphism influences platelet PAR1 receptor density and reactivity to SFLLRN.\textsuperscript{39} Although platelet P-selectin expression is increased in homozygous individuals for the PAR1 intrinsic variant in response to SFLLRN,\textsuperscript{39} we observed minimal variation in PP responses in healthy donors (3.9 \( \pm \) 1.0\%) (Figure 1C). Nevertheless, genetic variants may determine the suitability of healthy individuals for VITT/HIT testing. Donor selection is an issue for all functional assays. Hence, we propose that healthy donors undergo initial screening by LTA for response to the anti-CD9 antibody ALB6, and that reactive donors undergo secondary screening by flow cytometry using VITT plasma samples that induce known responses (equivocal, intermediate, and strong PP responses) to confirm suitability. We also suggest use of a positive control VITT plasma with each run.

In conclusion, induction of Fc\textgamma RIIa-dependent PP responses by patient plasma that were suppressible by heparin and IVlg is highly indicative of VITT in the correct clinical circumstance. Our assay modification of priming platelets from known Fc\textgamma RIIa-responsive donors with a GPCR agonist to potentiate ITAM signaling from platelet-activating immune complexes results in a sensitive and specific assay. This represents a functional platform to identify patients with platelet-activating antibodies and potentially predict treatment responses, with proven translational capacity.

**Acknowledgments**

The authors thank NSW Health for supplying the ChAdOx1 nCoV-19 vaccine and Jamie Triccas and Claudio Counoupas for supplying the recombinant protein HexaPro. They greatly appreciate Diane Criminale and the staff at CRGH Blood Collection Unit for assistance in blood collection. They also thank the members of the THANZ VITT advisory group and the THANZ VITT ELISA group.

This study is partly funded by NSW Health Pathology. V.M.C. is funded by a NSW Ministry of Health Senior Clinician Scientist Cardiovascular Capacity Building Grant.

**Authorship**

Contribution: C.S.M.L. designed and performed experiments, analyzed data, and wrote the manuscript; H.P.H.L., D.E.C., A.D., H.C., S.W., and D.C. performed flow cytometry experiments and analyzed data; F.H.P. performed multplate MEA; D.D., M.K., and T.A.B. provided serum samples; G.R.I. provided recombinant protein HexaPro. They greatly appreciated Diane Criminale and the staff at CRGH Blood Collection Unit for assistance in blood collection. They also thank the members of the THANZ VITT advisory group and the THANZ VITT ELISA group.

This study is partly funded by NSW Health Pathology. V.M.C. is funded by a NSW Ministry of Health Senior Clinician Scientist Cardiovascular Capacity Building Grant.

Conflict-of-interest disclosure: V.M.C. holds a US patent (“Selective targeting of procoagulant platelets”; US15/521435). C.S.M.L. and V.M.C. hold International (PCT) Patent Application No. PCT/AU2021/051233. The remaining authors declare no competing financial interests.

ORCID profiles: C.S.M.L., 0000-0002-3851-9364; D.E.C., 0000-0001-9602-7213; I.T.E., 0000-0003-0348-0839; E.J.F., 0000-0002-2103-1661; S.M.H., 0000-0001-5712-124X; P.Y.-I.C., 0000-0001-9340-8125; E.E.G., 0000-0001-9453-9688; V.M.C., 0000-0001-5119-7470.

Correspondence: Vivien M. Chen, Department of Haematology, Ground Floor, Concord Hospital, Hospital Rd, Concord, NSW 2139, Australia; e-mail: vivien.chen@sydney.edu.au.
28. Handtke S, Wolff M, Zaninetti C, et al. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. *Blood*. 2021;137(26):3656-3659.

29. Reilly-Stitt C, Kitchen S, Jennings I, et al. Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: results from a UK National External Quality Assessment Scheme exercise April 2021. *J Thromb Haemost*. 2021;19(9):2263-2267.

30. Baker AT, Boyd RJ, Sarkar D, et al. The structure of ChAdOx1/AZD-1222 reveals interactions with CAR and PF4 with implications for vaccine-induced immune thrombotic thrombocytopenia. *bioRxiv*. Preprint posted online 24 May 2021.

31. Greinacher A, Selleng K, Palankar R, et al. Insights in ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). *Blood*. 2021;138(22):2256-2268.

32. Schönborn L, Thiele T, Kaderali L, Greinacher A. Decline in pathogenic antibodies over time in VITT. *N Engl J Med*. 2021;385(19):1815-1816.

33. Oldenburg J, Klamroth R, Langer F, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. *Hamostaseologie*. 2021;41(3):184-189.

34. Huynh A, Arnold DM, Moore JC, Smith JW, Kelton JG, Nazy I. Development of a high-yield expression and purification system for platelet factor 4. *Platelets*. 2018;29(3):249-256.

35. Ataei S, Taheri MN, Tamaddon G, et al. High-yield production of recombinant platelet factor 4 by harnessing and honing the gram-negative bacterial secretory apparatus. *PLoS One*. 2020;15(5):e0232661.

36. Clancy R, El Bannoudi H, Rasmussen SE, et al. Human low-affinity IgG receptor FcγRIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus. *J Thromb Haemost*. 2019;17(3):532-537.

37. Rollin J, Pouplard C, Sung HC, et al. Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. *Blood*. 2015;125(15):2397-2404.

38. Gruel Y, Vayne C, Rollin J, et al. Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGHT) and the literature. *Thromb Haemost*. 2020;120(7):1096-1107.

39. Dupont A, Fontana P, Bachelot-Loza C, et al. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. *Blood*. 2003;101(5):1833-1840.